 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | ASC10 / Ascletis
Enrollment change, Trial withdrawal: Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients (clinicaltrials.gov) - Nov 1, 2024
P1, N=0, Withdrawn, Sponsor: Ascletis Pharmaceuticals Co., Ltd.
N=32 --> 0 | Not yet recruiting --> Withdrawn
- ASC10 / Ascletis
In vivo evaluation of ASC10 against SARS-CoV-2 virus in K18-hACE2 mouse SARS-CoV-2 model (B / 12) - Feb 4, 2023 - Abstract #ECCMID2023ECCMID_4776;
- ||| ASC10 / Ascletis
Trial completion: Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects (clinicaltrials.gov) - Dec 16, 2022
P1, N=72, Completed, Sponsor: Ascletis Pharmaceuticals Co., Ltd.
N=32 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- || ASC10 / Ascletis
Enrollment closed: Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects (clinicaltrials.gov) - Dec 14, 2022
P1, N=72, Active, not recruiting, Sponsor: Ascletis Pharmaceuticals Co., Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || ASC10 / Ascletis
New P1 trial: Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients (clinicaltrials.gov) - Oct 27, 2022
P1, N=32, Not yet recruiting, Sponsor: Ascletis Pharmaceuticals Co., Ltd.
- ||| ASC10 / Ascletis
Enrollment open: Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects (clinicaltrials.gov) - Oct 12, 2022
P1, N=72, Recruiting, Sponsor: Ascletis Pharmaceuticals Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| ASC10 / Ascletis
New P1 trial: Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects (clinicaltrials.gov) - Aug 31, 2022
P1, N=72, Not yet recruiting, Sponsor: Ascletis Pharmaceuticals Co., Ltd.